(NASDAQ: HRMY) Harmony Biosciences Holdings's forecast annual revenue growth rate of 17.47% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 65.42%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.4%.
Harmony Biosciences Holdings's revenue in 2025 is $714,734,000.On average, 4 Wall Street analysts forecast HRMY's revenue for 2025 to be $48,352,098,827, with the lowest HRMY revenue forecast at $47,018,239,915, and the highest HRMY revenue forecast at $49,294,287,216. On average, 3 Wall Street analysts forecast HRMY's revenue for 2026 to be $57,725,181,599, with the lowest HRMY revenue forecast at $54,203,071,517, and the highest HRMY revenue forecast at $60,103,934,889.
In 2027, HRMY is forecast to generate $66,296,056,619 in revenue, with the lowest revenue forecast at $59,272,423,530 and the highest revenue forecast at $71,550,118,845.